Video
Dr. Gandara Discusses Third-Generation EGFR TKIs
Author(s):
In Partnership With:
David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Comprehensive Cancer Center, discusses examining third-generation EGFR TKIs in lung cancer.
David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Comprehensive Cancer Center, discusses examining third-generation EGFR TKIs in lung cancer.
Gandara says third-generation EGFR TKIs are exciting. CO-1686 and AZD9291 are two agents that are being looked at in several trials in different settings for patients that have EGFR-mutated lung cancer.
AstraZeneca, the maker of AZD9291, has recently signed an agreement with the National Cancer Institute to conduct study through the cooperative group, Gandara says. Gandara is the co-leader of this project team and is hopeful for proposals to incorporate AZD9291 in combination.
